INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader

January 22, 2024

https://www.prnewswire.com/news-releases/inovio-to-participate-in-virtual-fireside-chat-on-the-potential-treatment-of-recurrent-respiratory-papillomatosis-with-key-opinion-leader-302040262.html

Fireside Chat, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, January 24, 2024, at 12:00pm ET

PLYMOUTH MEETING, Pa., Jan. 22, 2024 /PRNewswire/ — INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in a virtual fireside chat on the potential treatment of Recurrent Respiratory Papillomatosis (RRP). INOVIO’s President and CEO, Dr. Jacqueline Shea, and Chief Medical Officer, Dr. Michael Sumner, will be joined by Dr. Simon Best, Otolaryngologist at Johns Hopkins University and a Principal Investigator in INOVIO’s Phase 1/2 trial with INO-3107.

Read more at prnewswire.com

Related news for (INO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.